This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Campus
  1. Article
  2. Source: Campus Sanofi
  3. 23 Oct 2023

Video: BRIGHT study

Author: Sanofi

Editorial Team

  

Prescribing Information Toujeo (insulin glargine 300 units/mL)

toujeo logo
Sanofi is here to support you and your patients.

Ask us your questions about our products, patient materials or organising a meeting.

BRIGHT study

In this 7-minute video Dr. Alice Cheng tells you about the BRIGHT study, the head-to-head trial comparing Toujeo® vs insulin degludec 100 units/mL meeting the primary endpoint. She tells about the results and why they are relevant and important to her clinical practices, in helping the right patients on the right treatment.

SEE MORE FROM SCIENCE

Toujeo

Toujeo® is indicated as treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years. 

Patient Website

Find resources and support for your patients on Toujeo®. Help patients understand the basics of living and staying well with diabetes and how to have a positive start and experience with the medication prescribed to them.

MAT-XU-2205635 (v4.0) Date of Preparation: October 2023